

## Results of Annual General Meeting

**Melbourne, Australia; 16 November 2021:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Annual General Meeting of Shareholders was held today at 11.30 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and in patients with respiratory failure are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**

# Disclosure of Proxy Votes

## Cynata Therapeutics Limited

Annual General Meeting 2021

Tuesday, 16 November 2021



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	51,683,873	46,005,645 89.01%	5,088,318 9.85%	156,708	589,910 1.14%	48,976,055 89.83%	5,544,880 10.17%	236,708
2 Re-election of Dr Paul Wotton as a Director	P	56,449,824	38,709,245 68.57%	17,050,669 30.20%	179,676	689,910 1.22%	41,859,655 70.51%	17,507,231 29.49%	179,676
3 Approval of 10% Placement Facility	P	56,427,803	51,614,677 91.47%	4,108,216 7.28%	201,697	704,910 1.25%	54,700,087 92.17%	4,644,778 7.83%	201,697
4 Increase cap on Non-Executive Directors' remuneration	P	51,953,849	46,519,876 89.54%	4,826,532 9.29%	380,745	607,441 1.17%	49,577,317 90.37%	5,283,094 9.63%	391,245

